A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women
Phase of Trial: Phase II/III
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DPPIVinHIV
- 10 Jun 2017 Biomarkers information updated
- 25 Jun 2012 Actual patient number is 20 according to ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.